Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.
Raynaud's phenomenon often precedes the diagnosis of systemic sclerosis and is the first symptom of the disease in many cases. Antinuclear antibody positivity can assist in the early identification of cases of isolated Raynaud's phenomenon likely to progress to systemic sclerosis. However, the specific differences between rate of progression for different scleroderma hallmark antibodies is less clear. We review the predictive potential of ANA positivity and nailfold capillaroscopy for identifying cases of Raynaud's phenomenon which may progress to connective tissue diseases. We also have reviewed data from our own large scleroderma cohort to explore the relationship between antibody subtype and time to development of SSc. Duration of pre-existing Raynaud's phenomenon may be an important determinant of the profile of systemic sclerosis cases identified through screening. Ninety-five percent of our patients with isolated Raynaud's phenomenon, negative autoimmune serology on more than one visit and normal capillaroscopy score showed no progression to connective tissue disease. Duration of antecedent Raynaud's phenomenon differs between disease subsets and scleroderma-specific ANA patterns.
Centre for Rheumatology, Royal Free Hospital and UCL Medical School, London, UK.
Pia
P
Moinzadeh
Svetlana I
SI
Nihtyanova
Kevin
K
Howell
Voon H
VH
Ong
Christopher P
CP
Denton
D000974:Antibodies, Antinuclear / Q000276:immunology*; D018450:Disease Progression; D042241:Early Diagnosis; D006801:Humans; D011928:Raynaud Disease / Q000175:diagnosis* / Q000276:immunology*; D012594:Scleroderma, Localized / Q000175:diagnosis* / Q000276:immunology*
D000974:Antibodies, Antinuclear